Potent inhibition of Grb2 SH2 domain binding by non-phosphate- containing ligands

Journal of Medicinal Chemistry

Volumn 42, Issue 1, 1999, Pages 25-35

  Yao, Zhu Jun ^a   King, Richter C ^b   Cao, Tin ^b   Kelley, James ^a   Milne, George W A ^a   Voigt, Johannes H ^a   Burke Jr , Terrence R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PHENYLALANINE DERIVATIVE; PHOSPHATE; PRODRUG; PROTEIN TYROSINE KINASE; TRIPEPTIDE;

ARTICLE; BINDING AFFINITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; SEQUENCE HOMOLOGY; SURFACE PLASMON RESONANCE; SYNTHESIS;

EID: 0345434814     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980388x     Document Type: Article

References (51)

1. Wishart, M. J.; Dixon, J. E. Gathering STYX: phosphatase like form predicts functions for unique protein-interaction domains. Trends Biochem. Sci. 1998, 23, 301-306.
2. Mayer, B. J.; Gupta, R. Functions of SH2 and SH3 domains. Protein Modules Signal Transduct. 1998, 228, 1-22.
3. Zhou, S. Y.; Cantley, L. C. Recognition and specificity in protein tyrosine kinase-mediated signaling. Trends Biochem. Sci. 1995, 20, 470-475.
4. Burke, T. R., Jr.; Yao, Z.-J.; Smyth, M. S.; Ye, B. Phosphotyrosyl-based motifs in the structure-based design of protein-tyrosine kinase-dependent signal transduction inhibitors. Curr. Pharm. Des. 1997, 3, 291-304.
5. Lunney, E. A.; Para, K. S.; Rubin, J. R.; Humblet, C.; Fergus, J. H.; Marks, J. S.; Sawyer, T. K. Structure-based design of a novel series of nonpeptide ligands that bind to the pp60(src) SH2 domain. J. Am. Chem. Soc. 1997, 119, 12471-12476.
6. Pacofsky, G. J.; Lackey, K.; Alligood, K. J.; Berman, J.; Charifson, P. S.; Crosby, R. M.; Doresy, G. F., Jr.; Feldman, P. L.; Gilmer, T. M.; Hummel, C. W.; Jordan, S. R.; Mohr, C.; Shewchuk, L. M.; Sternbach, D. D.; Rodriguez, M. Potent dipeptide inhibitors of pp60c-src SH2 domain. J. Med. Chem. 1998, 41, 1894-1908.
7. Marseigne, I.; Roques, B. P. Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues. J. Org. Chem. 1988, 53, 3621-3624.
8. Burke, T. R., Jr.; Smyth, M.; Nomizu, M.; Otaka, A.; Roller, P. P. Preparation of fluoro- and hydroxy-4-phosphonomethyl-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine. J. Org. Chem. 1993, 58, 1336-1340.
9. Domchek, S. M.; Auger, K. R.; Chatterjee, S.; Burke, T. R.; Shoelson, S. E. Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide. Biochemistry 1992, 31, 9865-9870.
10. Burke, T. R., Jr.; Smyth, M. S.; Otaka, A.; Nomizu, M.; Roller, P. P.; Wolf, G.; Case, R.; Shoelson, S. E. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry 1994, 33, 6490-6494.
11. Xiao, S.; Rose, D. W.; Sasaoka, T.; Maegawa, H.; Burke, T. R.; Roller, P. P.; Shoelson, S. E.; Olefsky, J. M. Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J. Biol. Chem. 1994, 269, 21244-21248.
12. Wange, R. L.; Isakov, N.; Burke, T. R., Jr.; Otaka, A.; Roller, P. P.; Watts, J. D.; Aebersold, R.; Samelson, L. W. F2(Pmp)2-TAM-(zeta)3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling. J. Biol. Chem. 1995, 270, 944-948.
13. Stankovic, C. J.; Surendran, N.; Lunney, E. A.; Plummer, M. S.; Para, K. S.; Shahripour, A.; Fergus, J. H.; Marks, J. S.; Herrera, R.; Hubbell, S. E.; Humblet, C.; Saltiel, A. R.; Stewart, B. H.; Sawyer, T. K. The role of 4-phosphonodifluoromethyl- and 4-phosphonophenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg. Med. Chem. Lett. 1997, 7, 1909-1914.
14. Gilmer, T.; Rodriquez, M.; Jordan, S.; Crosby, R.; Alligood, K.; Green, M.; Kimery, M.; Wagner, C.; Kinder, D.; Charifson, P.; Hassell, A. M.; Willard, D.; Luther, M.; Rusnak, D.; Sternbach, D. D.; Mehrotra, M.; Peel, M.; Shampine, L.; Davis, R.; Robbins, J.; Patel, I. R.; Kassel, D.; Burkhart, W.; Moyer, M.; Bradshaw, T.; Berman, J. Peptide inhibitors of src SH3-SH2-phosphoprotein interactions. J. Biol. Chem. 1994, 269, 31711-31719.
15. Mehrotra, M. M.; Sternbach, D. D.; Rodriguez, M.; Charifson, P.; Berman, J. Alpha-dicarbonyls as "noncharged" arginine-directed affinity labels. Novel synthetic routes to alpha-dicarbonyl analogues of the pp60(c-src) SH2 domain-targeted phosphopeptide Ac-Tyr(OPO3H2)-Glu-Glu-Ile-Glu. Bioorg. Med. Chem. Lett. 1996, 6, 1941-1946.
16. Ye, B.; Akamatsu, M.; Shoelson, S. E.; Wolf, G.; Giorgetti-Peraldi, S.; Yan, X. J.; Roller, P. P.; Burke, T. R. L-O-(2-malonyl)-tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J. Med. Chem. 1995, 38, 4270-4275.
17. Burke, T. R.; Ye, B.; Akamatsu, M.; Ford, H.; Yan, X. J.; Kole, H. K.; Wolf, G.; Shoelson, S. E.; Roller, P. P. 4′-O-[2-(2-fluoromalonyl)]-L-tyrosine: A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. J. Med. Chem. 1996, 39, 1021-1027.
18. Margolis, B. The GRB family of SH2 domain proteins. Prog. Biophys. Mol. Biol. 1994, 62, 223-244.
19. Fretz, H.; Furet, P.; Schoepfer, J.; Garcia-Echeverria, C.; Gay, B.; Rahuel, J.; Caravatti, G. Targeting a hydrophobic patch on the survace of the Grb2-SH2 Domain Leads to high-affinity phosphotyrosine-containing peptide ligands. 15th American Peptide Symposium, Nashville, TN, June 14-19, 1997; Abstract P422.
20. After the submission of this manuscript, the full experimental for the work presented in ref 19 appeared in print: Furet, P.; Gay, B.; Caravatti, G.; Garcia-Escheverria, C.; Rahuel, J.; Schoepfer, J.; Fretz, H. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. J. Med. Chem. 1998, 41, 3442-3449.
21. Mndzhoyan, A. L.; Badalyan, V. E.; Aleksanyan, R. A.; Bkhiyan, M. T. Synthesis of some beta, gamma-disubstituted propylguanidines. Arm. Khim. Zh. 1969, 22, 795-804.
22. A more direct route to 11 has recently been reported; see ref 20.
23. Smyth, M. S.; Burke, T. R., Jr. Enantioselective synthesis of N-Boc and N-Fmoc protected diethyl 4-phosphonodifluoromethyl-L-phenylalanine; agents suitable for the solid-phase synthesis of peptides containing nonhydrolyzable analogues of O-phosphotyrosine. Tetrahedron Lett. 1994, 35, 551-554.
24. Burke, T. R., Jr.; Russ, P.; Lim, B. Preparation of 4-[bis(tertbutyl)phosphonomethyl]-N-Fmoc-DL-phenylalanine; a hydrolytically stable analogue of O-phosphotyrosine potentially suitable for peptide synthesis. Synthesis 1991, 11, 1019-1020.
25. Burke, T. R., Jr.; Yao, Z.-J.; He, Z.; Milne, G. W. A.; Wu, L.; Zhang, Z. Y.; Voigt, J. H. Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides. Tetrahedron 1998, 54, 9981-9994.
26. Dankort, D. L.; Wang, Z. X.; Blackmore, V.; Moran, M. F.; Muller, W. J. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol. Cell. Biol. 1997, 17, 5410-5425.
27. Fixman, E. D.; HolgadoMadruga, M.; Nguyen, L.; Kamikura, D. M.; Fournier, T. M.; Wong, A. J.; Park, M. Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cb1 and Gab1. J. Biol. Chem. 1997, 272, 20167-20172.
28. Tari, A. M.; Arlinghaus, R.; LopezBerestein, G. Inhibition of Grb2 and Crk1 proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem. Biophys. Res. Commun. 1997, 235, 383-388.
29. Ma, G. Z.; Lu, D.; Wu, Y.; Liu, J. X.; Arlinghaus, R. B. Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 1997, 14, 2367-2372.
30. Di Fiore, P. P.; Pierce, J. H.; Fleming, T. P.; Hazan, R.; Ullrich, A.; King, C. R.; Schlessinger, J.; Aaronson, S. A. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987, 51, 1063-1070.
31. Hudziak, R. M.; Schlessinger, J.; Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7159-7163.
32. Ben-Levy, R.; Paterson, H. F.; Marshall, C. J.; Yarden, Y. A single autophosphorylation site confers oncogenicity to the Neu/ ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 1994, 13, 3302-3311.
33. Xie, Y. M.; Pendergast, A. M.; Hung, M. C. Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu. J. Biol. Chem. 1995, 270, 30717-30724.
34. Rojas, M.; Yao, S. Y.; Lin, Y. Z. Controlling epidermal growth factor (EGF)-stimulated ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J. Biol. Chem. 1996, 271, 27456-27461.
35. Williams, E. J.; Dunican, D. J.; Green, P. J.; Howell, F. V.; Derossi, D.; Walsh, F. S.; Doherty, P. Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide. J. Biol. Chem. 1997, 272, 22349-22354.
36. Furet, P.; Gay, B.; GarciaEcheverria, C.; Rahuel, J.; Fretz, H.; Schoepfer, J.; Caravatti, G. Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain. J. Med. Chem. 1997, 40, 3551-3556.
37. Gay, B.; Furet, P.; GarciaEcheverria, C.; Rahuel, J.; Chene, P.; Fretz, H. Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands. Biochemistry 1997, 36, 5712-5718.
38. 2. J. Med. Chem. 1998, 41, 1741-1744.
39. Morelock, M. M.; Ingraham, R. H.; Betageri, R.; Jakes, S. Determination of receptor-ligand kinetic and equilibrium binding constants using surface plasmon resonance: Application to the lck SH2 domain and phosphotyrosyl peptides. J. Med. Chem. 1995, 38, 1309-1318.
40. Oligino, L.; Lung, F. D. T.; Sastry, L.; Bigelow, J.; Cao, T.; Curran, M.; Burke, T. R., Jr.; Wang, S. M.; Krag, D.; Roller, P. P.; King, C. R. Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J. Biol. Chem. 1997, 272, 29046-29052.
41. Absolute configurations of the Pmp residues were not determined unambiguously, rather the L-configuration was assigned to the enantiomer illiciting the more potent inhibition.
42. Mikol, V.; Baumann, G.; Keller, T. H.; Manning, U.; Zurini, M. G. M. The crystal structures of the SH2 domain of p56(lck) complexed with two phosphonopeptides suggest a gated peptide binding site. J. Mol. Biol. 1995, 246, 344-355.
43. Shahripour, A.; Plummer, M. S.; Lunney, E. A.; Para, K. S.; Stankovic, C. J.; Rubin, J. R.; Humblet, C.; Fergus, J. H.; Marks, J. S.; Herrera, R.; Hubbel, S. E.; Saltiel, A. R.; Sawyer, T. K. Novel phosphotyrosine mimetics in the design of peptide ligands for pp60src SH2 domain. Bioorg. Med. Chem. Lett. 1996, 6, 1209-1214.
44. Kraus, M. H.; Popescu, N. C.; Amsbough, S. C.; King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987, 6, 605-610.
45. Rojas, M.; Yao, S. Y.; Donahue, J. P.; Lin, Y. Z. An alternative to phosphotyrosine-containing motifs for binding to an SH2 domain. Biochem. Biophys. Res. Commun. 1997, 234, 675-680.
46. After submission of this manuscript, it was reported that actinomycins are able to potently inhibit Grb2 SH2 domain binding: Nam, J.-Y.; Kim, H.-K.; Son, K.-H.; Kim, S.-U.; Kwon, B.-M.; Han, M. Y.; Chung, Y. J.; Bok, S. H. Actinomycin D, C2 and VII, inhibitors of Grb2-Shc interaction produced by streptomyces. Bioorg. Med. Chem. Lett. 1998, 8, 2001-2002.
47. Rahuel, J.; Gay, B.; Erdmann, D.; Strauss, A.; GarciaEcheverria, C.; Furet, P.; Caravatti, G.; Fretz, H.; Schoepfer, J.; Grutter, M. G. Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode. Nature Struct. Biol. 1996, 3, 586-589.
48. Sastry, L.; Lin, W. H.; Wong, W. T.; Difiore, P. P.; Scoppa, C. A.; King, C. R. Quantitative analysis of Grb2-Sos1 interaction: The N-terminal SH3 domain of Grb2 mediates affinity. Oncogene 1995, 11, 1107-1112.
49. Allen, M. C.; Brundish, D. E.; Fullerton, J. D.; Wade, R. Tritiated peptides. Part 15. Synthesis of tritium labeled biologically active analogues of somatostatin. J. Chem. Soc., Perkin Trans. I 1986, 989-1004.
50. Condon-Gueugnot, S.; Leonel, E.; Nedelec, J. Y.; Perichon, J. Electrochemical arylation of activated olefins using a nickel salt as catalyst. J. Org. Chem. 1995, 60, 7684-7687.
51. Searles, S. The reaction of trimethylene oxide with Grignard reagents and organolithiumcompounds. J. Am. Chem. Soc. 1951, 73, 124.